Epizyme Appoints Andrew Singer As Chief Financial Officer

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Andrew Singer will join the Company as Chief Financial Officer on February 9th. Mr. Singer brings nearly 20 years of financial experience in the life sciences field and was previously Managing Director, Healthcare Investment Banking, in the Life Sciences Group at RBC Capital Markets Corporation, part of RBC Financial Group.

Help employers find you! Check out all the jobs and post your resume.